Clinical Trial Update: Combination of Anti-PD-1 and NK Immunotherapy for Recurrent Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating combination of anti-PD-1 therapy with NK cell–based immunotherapy for recurrent malignant solid tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Solid Tumor

Drugs mentioned

• Anti-PD-1 therapy
• NK immunotherapy (natural killer cell-based immunotherapy)

Snippet

Sponsor: Fuda Cancer Hospital, Guangzhou | Conditions: Malignant Solid Tumour | Phase 1, Phase 2 | Status: COMPLETED